13 research outputs found
Cumulative recruitment to the study by month.
<p>Cumulative recruitment to the study by month.</p
Cumulative recruitment to the study by month.
<p>Cumulative recruitment to the study by month.</p
Baseline demographic and clinical characteristics, by randomised treatment arm.
<p>Baseline demographic and clinical characteristics, by randomised treatment arm.</p
Clinical characteristics at baseline and 96 weeks in the losartan and placebo treated patients.
<p>Clinical characteristics at baseline and 96 weeks in the losartan and placebo treated patients.</p
Consort diagram of patient recruitment and retention in the study.
<p>Consort diagram of patient recruitment and retention in the study.</p
Summary statistics for liver fibrosis assessed by the NASH CRN criteria [27] at baseline and 96 weeks by trial arm.
<p>Summary statistics for liver fibrosis assessed by the NASH CRN criteria [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175717#pone.0175717.ref027" target="_blank">27</a>] at baseline and 96 weeks by trial arm.</p
Number of patients prescribed Angiotensin Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARB) in the Newcastle Primary care cohort (n = 149,097) from the time of conception (2007–8), to obtaining funding (2009), to recruitment beginning (2011).
<p>Number of patients prescribed Angiotensin Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARB) in the Newcastle Primary care cohort (n = 149,097) from the time of conception (2007–8), to obtaining funding (2009), to recruitment beginning (2011).</p
Change in fibrosis stage from baseline to 96 weeks.
<p>Change in fibrosis stage from baseline to 96 weeks.</p
An overview of a detailed analysis of eligibility for all patients who had a liver biopsy to diagnose or stage NAFLD in Newcastle between Jan 2011 and Sept 2012 (21 months).
<p>An overview of a detailed analysis of eligibility for all patients who had a liver biopsy to diagnose or stage NAFLD in Newcastle between Jan 2011 and Sept 2012 (21 months).</p
Reported adverse events in the study population (ITT analysis).
<p>Reported adverse events in the study population (ITT analysis).</p